Zenas BioPharma, Inc. financial data

Symbol
ZBIO on Nasdaq
Location
Waltham, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 12 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 589% %
Debt-to-equity 28% %
Return On Equity -74% % -158%
Return On Assets -58% %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 53,679,166 shares 28%
Common Stock, Shares, Outstanding 42,213,465 shares 1%
Entity Public Float $0 USD
Common Stock, Value, Issued $4,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 42,159,340 shares 448%
Weighted Average Number of Shares Outstanding, Diluted 42,159,340 shares 448%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $0 USD
Revenue from Contract with Customer, Excluding Assessed Tax $10,000,000 USD
Research and Development Expense $161,501,000 USD 2.6%
General and Administrative Expense $49,196,000 USD 77%
Operating Income (Loss) $200,697,000 USD -28%
Nonoperating Income (Expense) $11,041,000 USD -55%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $189,656,000 USD -33%
Income Tax Expense (Benefit) $20,000 USD
Net Income (Loss) Attributable to Parent $189,900,000 USD -47%
Earnings Per Share, Basic 31 USD/shares 76%
Earnings Per Share, Diluted 31 USD/shares 76%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $115,565,000 USD -68%
Cash, Cash Equivalents, and Short-term Investments $301,600,000 USD -22%
Assets, Current $296,642,000 USD -25%
Property, Plant and Equipment, Net $50,000 USD -66%
Operating Lease, Right-of-Use Asset $807,000 USD 102%
Other Assets, Noncurrent $13,802,000 USD 53%
Assets $322,018,000 USD -20%
Accounts Payable, Current $6,444,000 USD -57%
Employee-related Liabilities, Current $8,757,000 USD 42%
Accrued Liabilities, Current $45,359,000 USD 59%
Liabilities, Current $52,421,000 USD 19%
Operating Lease, Liability, Noncurrent $180,000 USD
Liabilities $125,590,000 USD 185%
Accumulated Other Comprehensive Income (Loss), Net of Tax $69,000 USD -228%
Retained Earnings (Accumulated Deficit) $524,686,000 USD -57%
Stockholders' Equity Attributable to Parent $196,428,000 USD -45%
Liabilities and Equity $322,018,000 USD -20%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $37,051,000 USD -94%
Net Cash Provided by (Used in) Financing Activities $99,000 USD
Net Cash Provided by (Used in) Investing Activities $86,274,000 USD -392055%
Common Stock, Shares Authorized 175,000,000 shares 0%
Common Stock, Shares, Issued 42,213,465 shares 1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $123,278,000 USD -526%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $115,565,000 USD -68%
Deferred Tax Assets, Valuation Allowance $90,295,000 USD 127%
Deferred Tax Assets, Gross $90,858,000 USD 127%
Operating Lease, Liability $798,000 USD -100%
Depreciation $23,000 USD -30%
Payments to Acquire Property, Plant, and Equipment $18,000 USD -18%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $190,023,000 USD -33%
Lessee, Operating Lease, Liability, to be Paid $834,000 USD
Operating Lease, Liability, Current $618,000 USD 61%
Lessee, Operating Lease, Liability, to be Paid, Year Two $138,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year One $457,000 USD 4.1%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure -38%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $36,000 USD
Deferred Tax Assets, Operating Loss Carryforwards $29,605,000 USD 197%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 25,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Additional Paid in Capital $721,179,000 USD 3.9%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense $24,262,000 USD 158%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%